Assessment of the cost-effectiveness of Australia's risk-sharing agreement for direct-acting antiviral treatments for hepatitis C: a modelling study.
Scott DN, Palmer MA, Tidhar MT, Stoove PM, Sacks-Davis DRS, Doyle AJS, Pedrana DAJ, Thompson PA, Wilson PDP, Hellard PM
Injecting network structure determines the most efficient strategy to achieve Hepatitis C elimination in people who inject drugs.
Brown C, Siegele M, Wright M, Cook C, Parkes J, I Khakoo S, Sacks-Davis R, Buchanan RM
Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis.
Arum C, Fraser H, Artenie AA, Bivegete S, Trickey A, Alary M, Astemborski J, Iversen J, Lim AG, MacGregor L, Morris M, Ong JJ, Platt L, Sack-Davis R, van Santen DK, Solomon SS, Sypsa V, Valencia J, Van Den Boom W, Walker JG, Ward Z, Stone J, Vickerman P, Homelessness, HIV, and HCV Review Collaborative Group
Estimating the number of new hepatitis C infections in Australia in 2015, prior to the scale-up of direct-acting antiviral treatment.
Palmer AY, Wilkinson A, Aitken C, Dietze P, Dore GJ, Maher L, Sacks-Davis R, Stoove M, Wilson D, Hellard M, Scott N
Modelling the impact of reducing control measures on the COVID-19 pandemic in a low transmission setting.
Scott N, Palmer A, Delport D, Abeysuriya R, Stuart R, Kerr CC, Ministry D, Klein D, Sacks-Davis R, Heath K, Hainsworth S, Pedrana A, Stoové M, Wilson D, Hellard ME
COVID-19 Global Infectious Disease Threats Infectious Disease Modelling
Modelling the impact of relaxing COVID-19 control measures during a period of low viral transmission.
Scott N, Palmer A, Delport D, Abeysuriya R, Stuart RM, Kerr CC, Mistry D, Klein DJ, Sacks-Davis R, Heath K, Hainsworth SW, Pedrana A, Stoove M, Wilson D, Hellard ME
COVID-19